PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a ...

PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About PaciraPacira delivers innovative, non-opioid pain therapies to ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Pacira BioSciences (PCRX) announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable suspension), ensuring protection against generics in the market through 2044. The ‘940 patent is the first from a new family of patents related to Exparel produced by Pacira’s enhanced large-scale manufacturing process in San Diego, which received FDA approval in February 2024.Exparel is Pacira’s flagship pain-manage ...

-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the ‘940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The ‘940 patent, entitled “Manufacturing of Bupivacaine Multivesicular Liposomes” pr ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Company Overview - Pacira BioSciences, Inc. (NASDAQ: PCRX) stock is currently trading at $18, a significant decline from its peak of $115 per share in 2015 and over $75 per share in March 2022 [2]. Stock Performance - The stock has experienced a near-constant decline, reaching a low of approximately $13 in mid-August [2]. Investment Insights - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch for, buy and sell ratings, product sales forecasts, and integrated financial statements [2].

Core Viewpoint - Pacira BioSciences, Inc. reported third-quarter 2024 adjusted earnings of 79 cents per share, exceeding the Zacks Consensus Estimate of 72 cents, while total revenues reached $168.6 million, a 3% year-over-year increase but slightly below the consensus estimate of $169 million [1]. Financial Performance - Adjusted earnings for Q3 2024 were 79 cents per share, up from 72 cents in the same quarter last year [1]. - Total revenues for the quarter were $168.6 million, a 3% increase year over year, but missed the Zacks Consensus Estimate of $169 million [1]. - Exparel's net product sales were $132 million, reflecting a 3% increase from the previous year and surpassing the Zacks Consensus Estimate of $131.2 million [3]. - Zilretta's net product sales were $28.4 million, slightly down year over year and below the Zacks Consensus Estimate of $30.6 million [5]. - Iovera's net product sales were $5.7 million, an 8% increase from the previous year, but also missed the Zacks Consensus Estimate of $5.99 million [5]. - Royalty revenues amounted to $0.9 million, showing significant year-over-year growth [6]. Expenses - Research and development (R&D) expenses (excluding stock-based compensation) were $17.3 million, down 7% from the previous year due to lower product development and regulatory costs [7]. - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) increased by 10% year over year to $65 million, primarily due to litigation costs and increased investments in commercial and market access organizations [8]. Financial Guidance - The company maintained its 2024 financial guidance, expecting total revenues between $680 million and $705 million [9]. - Adjusted R&D expenses are projected to be between $70 million and $80 million, while adjusted SG&A expenses are expected to range from $245 million to $265 million [9]. - The adjusted gross margin is anticipated to be between 74% and 76% for 2024 [9]. Recent Developments - The Centers for Medicare and Medicaid Services (CMS) proposed a rule for 2025 that includes Exparel among non-opioid treatments eligible for separate Medicare reimbursement, effective January 1, 2025 [10][11]. - A permanent product-specific J-code for Exparel was issued by CMS, set to take effect on January 1, 2025, to improve insurance coverage for the drug [12]. - The company faced a setback when a U.S. District Court ruled that its '495 patent for Exparel is not valid, and it is currently evaluating legal options [13].

Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.72%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.89, delivering a surprise of 21.92%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other J ...